Table 3

Characteristics of included studies investigating or reporting adverse effects in patients administered with either levetiracetam (LEV) or phenytoin (PHT) in association with brain tumour-related epilepsy

AuthorYearStudy designStudy sizeType of AEDDosageAdverse effectsSevere adverse effectsFollow-up
Forstyh et al 19 2003Randomised trial46PHT15 mg/kg1120–31 months
Newton et al 25 2007Retrospective study13LEV500–3000 mg ×1301 month to 4 years
Merrell et al 31 2010Retrospective study76 patients (51 LEV)LEV
PHT		NA
NA		3
5		0
0		6 months
Usery et al 26 2010Prospective open label17LEV500–3000 mg ×1601 month
Zachenhofer et al 27 2011Retrospective study78LEV1000–3000 mg ×1320–31 months
Bähr et al 32 2012Prospective study25LEV1000–2000 mg ×1301 month
Gokhale et al 29 2013Retrospective study165LEV1000–3000 mg ×1707 days
Fuller et al 24 2013Randomised trial74
(36 LEV)		LEV
PHT		500–1000 mg
300–900 mg		1
8		1
6		3 months
Lee et al 34 2013Retrospective study51LEV500–3000 mg ×1501–24 months
Wychowski et al 20 2013Retrospective study28
13		LEV
PHT		500 mg ×2
NA		5
6		0
3		12 months
Garbossa et al 17 2013Retrospective study91LEV500 mg ×2106 months
Wu et al 14 2013Randomised trial62PHT100 mg per 8 hours9312 months
Rossetti et al 35 2014Randomised trial25LEV500–3000 mg ×14212 months
de Oliveira et al 33 2014Retrospective study85PHTNA316 months
Iuchi et al 28 2015Randomised trial146 (73 LEV)LEV
PHT		500 mg/kg per 12 hours
15–18/kg per 12 hours		3
5		0
0		7 days

  • AED, antiepileptic drugs; NA, not applicable.